c‐erbB‐2 oncogene expression in ovarian cancer

Haldane, J. S.; Hird, V.; Hughes, Christine M.; Gullick, William J.

doi:10.1002/path.1711620309

Cited by 84 publications

(27 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The proportion of tumors showing a definite immunostaining for HER2/neu protein (scores 2+/3+) was similar to the percentages of immunostaining reported in previous studies [13, 18, 19, 20]. …”

Section: Discussionsupporting

confidence: 72%

“…Like other authors [13, 18, 19, 20, 21], we also found no statistical correlation between HER2/neu protein overexpression and age, histological subtype, or residual tumor, nor did we find any relationship between overexpression and FIGO stage, confirming that activation of HER2/neu overexpression can occur both in early and late stages of disease [22, 23]. …”

Section: Discussionsupporting

confidence: 68%

See 1 more Smart Citation

HER2/neu Oncoprotein Overexpression in Epithelial Ovarian Cancer: Evaluation of its Prevalence and Prognostic Significance

Verri¹,

Guglielmini²,

Puntoni³

et al. 2005

Oncology

120

View full text Add to dashboard Cite

Introduction: The HER2/neu proto-oncogene encodes a transmembrane receptor protein involved in the development and progression of the majority of cancers. Prior studies have shown that HER2/neu oncogene is overexpressed in approximately 15–30% of ovarian carcinomas. However findings regarding the overexpression and prognosis are still conflicting. Methods: Our retrospective study was performed on 194 ovarian carcinoma tissues obtained at the time of first surgery. The staining procedure for HER2/neu overexpression was performed using a polyclonal antibody. Results: HER2/neu overexpression was found in 53 out of 194 (27.3%) investigated cases of which 26 (13.4%) carcinomas were weakly positive (score 1+) and 27 (13.9%) moderately (score 2+) to intensely positive (score 3+). No significant relationship was found between HER2/neu score and main clinical and pathological features. Significant difference in overall survival was evident between negative women (0/1+) and positive women (2+/3+): 48 and 29 months, respectively (p = 0.04). In multivariate analysis HER2/neu overexpression appeared to be the only variable significantly correlated with progression and death. CA125 normalization at 3 and 6 months appeared a strong predictor of progression and survival. Conclusion: In this study HER2/neu overexpression was associated with an increased risk of progression and death, especially among women with FIGO Stage I and II ovarian carcinoma.

show abstract

Section: Discussionsupporting

confidence: 72%

Section: Discussionsupporting

confidence: 68%

HER2/neu Oncoprotein Overexpression in Epithelial Ovarian Cancer: Evaluation of its Prevalence and Prognostic Significance

Verri¹,

Guglielmini²,

Puntoni³

et al. 2005

Oncology

120

View full text Add to dashboard Cite

show abstract

“…Berchuck et al 34 reported a poorer prognosis for OC patients in whom HER-2 was overexpressed, in contrast to Haldane et al and Rubin et al, 11,35 who did not find any adverse prognostic significance on survival for HER-2 overexpression. Buller et al 36 analyzed 11 familial OC patients and found that 6 of the patients with tumors that were negative for HER-2 had a prolonged 5-year survival rate of 67% in comparison with a 5-year survival rate of 17% in the patients with nonfamilial OC.…”

Section: Discussionmentioning

confidence: 93%

Distribution of HER‐2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma

Høgdall

Christensen

Kjær

et al. 2003

Cancer

125

View full text Add to dashboard Cite

BACKGROUNDThe HER‐2 (Human Epidermal Growth factor receptor‐2, also known as c‐erb‐2/neu) protooncogene encodes a transmembrane receptor protein, Mr 185,000. Studies have shown that the HER‐2 oncogene is overexpressed in approximately 25–30% of ovarian carcinoma (OC) cases, but to the authors' knowledge, to date no consensus regarding overexpression and prognosis has been possible. The objective of the current study was first to analyze the presence of HER‐2 overexpression in tissue from Danish OC patients and correlate the distribution of HER‐2 overexpression with clinical and biochemical data and second to investigate the value of HER‐2 overexpression as a prognostic marker in OC and to compare this value with the prognostic value of other biochemical markers.METHODSThe study population was comprised of the first 181 patients diagnosed with epithelial OC who were included in the MALOVA study. The staining procedure for HER‐2 overexpression was performed using the p185 antibody.RESULTSHER‐2 overexpression was found in 95 of the 181 investigated cases (52.5%), in which 71 carcinomas (39.2%) were weakly positive (1+) and 24 carcinomas (13.3%) were moderately (2+) to intensely positive (3+). Increased HER‐2 expression was found to be correlated with reduced survival. Significant differences in survival between patients with (1+, 2+, and 3+) and those without HER‐2 overexpression were found for patients with International Federation of Gynecology and Obstetrics (FIGO) Stage I, Stage III, and Stage III/IV OC (Stage I: P = 0.021; Stage III: P = 0.0078; and Stage III/IV: P = 0.0054). Multivariate survival analyses including all 181 OC patients demonstrated that HER‐2 overexpression is a prognostic marker (P = 0.003) together with disease stage, serum tetranectin level, and patient age. For patients with Stage III OC, the only independent prognostic factors detected were HER‐2 overexpression (P = 0.009) and serum tetranectin level (P ≤ 0.0001).CONCLUSIONSThe results of the current study show that HER‐2 overexpression has prognostic value both in univariate and multivariate survival analyses. Therefore, the clinical relevance of this observation should be established conclusively by therapy that targets HER‐2 in a prospective Phase II clinical trial. Cancer 2003;98:66–73. © 2003 American Cancer Society.DOI 10.1002/cncr.11476

show abstract

“…In breast and ovarian cancers localisation of the epidermal growth factor (EGF) receptor status and HER-2/neu oncogene product have been shown to correlate well with survival (Sainsbury, 1987;Haldane et al, 1990). These factors are primarily thought to reflect differences in proliferation rates of the tumours, and are not directly related to the mechanism of action of any specific agent used in their treatment.…”

mentioning

confidence: 99%

Glutathione S-transferase expression in benign and malignant ovarian tumours

Green

Robertson²,

Clark³

1993

Br J Cancer

View full text Add to dashboard Cite

Summary Glutathione S-transferase sub-types a, 1t and were assessed by immunocytochemistry in 109 biopsies of ovarian tissue, comprising malignant epithelial tissue in 86 cases and tissue of ovarian origin considered to be normal in 23. Glutathione S-transferase n was the most prevalent, being present in all except one malignant epithelium studied and 83% of non-malignant tissue. There were no significant differences in the overall distribution of positive staining for a, and in the malignant and non-malignant biopsies, although the intensity of staining was greater in the malignant epithelium. Stromal staining was in general more pronounced in the malignant biopsies, and this was particularly prominent in the case of the a sub-type. Positive staining was seen more frequently in the less well-differentiated tumours, and a diffuse cytoplasmic pattern was the most common observation in tumours of moderate and poor differentiation. There was no significant association between survival and the presence or absence of sub-type staining of a and sub-type. For the sub-type at, patient survival was found to correlate with the intensity of staining (on a 0-+ + + scale). Those patients showing resistance to cytotoxic chemotherapy were found to have a higher intensity of staining for GSTi than responding patients.

show abstract

c‐erbB‐2 oncogene expression in ovarian cancer

Cited by 84 publications

References 13 publications

HER2/neu Oncoprotein Overexpression in Epithelial Ovarian Cancer: Evaluation of its Prevalence and Prognostic Significance

HER2/neu Oncoprotein Overexpression in Epithelial Ovarian Cancer: Evaluation of its Prevalence and Prognostic Significance

Distribution of HER‐2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma

Glutathione S-transferase expression in benign and malignant ovarian tumours

Contact Info

Product

Resources

About